Premium
Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis
Author(s) -
Dar Saleem,
Mundle Suneel,
Andric Tanja,
Qawi Huma,
Shetty Vilasini,
Reza Samina,
Mativi B. Yifwayimare,
Allampallam Krishnan,
Ali Ambereen,
Venugopal Parameswaren,
Gezer Sefer,
BroadyRobinson LaTanya,
Cartlidge John,
Showel Margaret,
Hussaini Seema,
Ragasa Deborah,
Ali Irfan,
Chaudhry Ambreen,
Waggoner Samina,
Lisak Laurie,
Huang RayWin,
Raza Azra
Publication year - 1999
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1999.tb01727.x
Subject(s) - apoptosis , myelodysplastic syndromes , cytokine , bone marrow , medicine , tumor necrosis factor alpha , in vivo , biopsy , intramedullary rod , pathology , immunology , cancer research , gastroenterology , biology , surgery , biochemistry , microbiology and biotechnology
Spontaneous intramedullary apoptosis was measured in bone marrow (BM) biopsies of 175 patients with myelodysplastic syndromes (MDS) using in situ end‐labeling (ISEL) of fragmented DNA. Two groups of high ( n = 71) versus low ( n = 43) levels of apoptosis were identified while 61 patients were ISEL‐negative. Semiquantitative assessment of 3 cytokines, the number of macrophages and in vivo labeling indices (LI) were also determined from consecutive sections of the biopsy. Patients with high apoptosis levels tended to have a high LI ( p = 0.013), more macrophages in their BM biopsies ( p = 0.006) and higher tumor necrosis factor alpha (TNF‐α) levels (not significant) compared to patients with no apoptosis. In addition, low risk MDS patients had significantly lower rates of apoptosis ( p = 0.047) and lower levels of TNF‐α ( p = 0.055) compared to high‐risk MDS patients. We conclude that the genesis of cytopenias in MDS is of multifactorial origin and that cytokine‐associated apoptosis clearly identifies a distinct biological subgroup of patients who may benefit selectively by use of anti‐cytokine therapies.